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Considerations on accuracy,
pattern and possible
underlying factors of brain
microbleed progression in
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vascular pathology
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Abstract
Objective: To analyse brain microbleed (BMB) progression, its possible underlying factors, and
the influence of inter-observer differences, in older individuals with none or mild vascular
pathology.
Methods: This study analysed magnetic resonance images, cognitive, demographic and labora-
tory data from all individuals from the Alzheimer’s Disease (AD) Neuroimaging Initiative database
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who had the required sequences for identifying BMBs over three consecutive years at the time
the database was accessed (January 2016). BMBs were assessed independently by two observers
with similar levels of experience.
Results: A total of 291 patients were included in the study. The number of individuals with BMBs
and the number of BMBs per individual slightly and nonsignificantly increased across three con-
secutive years (Y1: 55/291 [19%]; Y2: 61/291 [21%]; Y3: 66/291 [23%]) with 1–2 BMBs and (Y1:
11/291 [4%]; Y2: 12/291 [4%]; Y3: 14/291 [5%]) with  3 BMBs. Both observers identified a
similar pattern of BMB prevalence and progression in each cognitive group (normal< early/late
mild cognitive impairment (MCI)>AD patients) despite inter-observer differences (1.5 BMBs,
95% confidence interval –3.7, 6.2], j¼0.543), which were mainly in the cortex. Serum cholesterol
was the main predictor of change in BMB count between time-points but did not predict overall
progression.
Conclusions: Inter-observer differences are always present and it is difficult to ascertain their
influence in the analysis of BMB progression, which was observed in cognitively normal and MCI
individuals, but not in AD patients. This should be confirmed in further studies.
Keywords
Microbleeds, magnetic resonance imaging, ageing, progression, longitudinal, inter-observer
differences
Date received: 6 October 2017; accepted: 29 December 2017
Introduction
Cognitive decline is an ever-increasing chal-
lenge to health and social care systems
worldwide due to the growing elderly pop-
ulation. The availability of biomarkers and
improved understanding of factors that
contribute to heterogeneity in cognitive
decline are required to improve diagnosis
and prognosis. Small chronic brain haemor-
rhages occurring with impaired small vessel
wall integrity, known as brain microbleeds
(BMBs),1 are commonly found in elderly
individuals and have been linked to key
hypotheses in the neuro-pathogenesis of
the most common form of dementia (i.e.
Alzheimer’s Disease [AD]), namely the
‘amyloid cascade’2 and the ‘vascular
hypothesis’.3 However, the clinical effect
of BMBs on cognition is an evolving
research field.4 The prevalence of BMBs at
different stages within the continuum of
cognitive decline, reported by a recent
review of multiple studies using different
magnetic resonance imaging (MRI) sequen-
ces and different magnet strengths,1 are
shown in Figure 1.
A further exploratory analysis on the
progression pattern of brain mineral depo-
sition, including BMBs, as a differential
indicator of cognitive decline in a cross-
sectional sample of 200 individuals aged
55–90 years old (58 cognitively normal
[CN], 127 with mild cognitive impairment
[MCI] and 15 with AD) observed a similar
trend, of a higher count in the number of
BMBs in individuals with MCI compared
with those with AD.5 Indeed, a number of
studies have identified a lack of association
between BMBs and cognitive function in
AD patients,6,7 indicating that BMBs may
not be present in patients with severe AD at
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all6 and that cognitive decline in AD may
be independent of BMB number.8 MCI
could be manifested on different neurocog-
nitive disorders. However, as MCI is a stage
in the continuum of cognitive decline that
leads to AD, exploring the manifestations
at each stage of this continuum would cer-
tainly lead to a better understanding of the
AD pathogenesis. Few longitudinal studies
have considered the predictive value of
BMB detection on the progression of cog-
nitive decline.9,10 A study found MCI par-
ticipants with BMBs were twice as likely to
progress to dementia than those without
BMBs.10 Another study investigated AD
patients and found that patients with
BMBs were more cognitively impaired
than patients without BMBs, despite
having similar disease duration.9 Although
these studies suggest that BMBs may have a
potential predictive value for progression of
cognitive decline, the evidence is limited.
The variability in the outcome of the assess-
ment of BMBs when magnetic field
strengths and sequence parameters differ is
known;11 and it has been considered the
main limitation in the analyses of BMB
progression. To the best of our knowledge,
and in agreement with a recent review on
the reproducibility and variability of MRI
markers in cerebral small vessel disease,11
no study has assessed the reproducibility
of any longitudinal measurement for
BMBs.
This study investigated BMB progres-
sion over three consecutive years in groups
of individuals with different cognitive
status: CN, early MCI (EMCI), late MCI
(LMCI), and AD, with the hypothesis that
BMB prevalence and count progress in CN
and MCI individuals, but not in AD
patients. The study also evaluated putative
risk factors for BMB progression at each
time-point and analysed the influence of
inter-observer differences on the assessment
of BMB progression. Of note, the use of the
term ‘progression’ not only refers to wheth-
er BMB prevalence (i.e. the proportion of
patients with BMBs) and count (i.e. the
individual number of BMBs per patient)
increased (i.e. progressed), but also if it
decreased (i.e. regressed), or remained
stable from one year to the next.
Patients and methods
Clinical data extraction from the
ADNI database
Data used in the preparation of this article
were obtained from the Alzheimer’s Disease
Neuroimaging Initiative (ADNI) data-
base.12 The ADNI was launched in 2003
as a public-private partnership, led by
Principal Investigator Michael W Weiner,
MD. The primary goal of ADNI has been
to evaluate whether serial MRI, positron
emission tomography (PET), other
biological markers, and clinical and
Figure 1. Schematic representation of the continuum of cognitive decline: from cognitively normal to
dementia, as defined by the American Psychiatric Association, and the prevalence of brain microbleeds
(BMBs) at its different stages.1 The colour version of this figure is available at: http://imr.sagepub.com.
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neuropsychological assessments can be
combined to measure their progression
through the process of normal ageing to
EMCI, to LMCI, to dementia or AD.13
Relevant clinical information for all
patients, selected based on clinical plausibil-
ity and/or previous research, was extracted
from the ADNI database as per Table 1.14–39
Data collection was approved by the corre-
sponding review boards of the United States
National Institutes of Health and the
Canadian Institutes of Health Research.12
Written informed consent was obtained
from the ADNI participants or their next-
of-kin.
Study participants
Patients were identified from the ADNI
database, accessed in January 2016, using
the following selection criteria: (i) three con-
secutive study visits at 12 months apart; (ii)
structural MRI acquisitions at each visit,
including T1-weighted (MPRAGE) and
T2*-weighted (GRE) sequences, to assess
BMBs. Patient selection was done blind to
any clinical, demographic or cognitive data.
MRI acquisition
The T2*-weighted (GRE) sequence, which
was the primary sequence used for identify-
ing BMBs, was consistently acquired in
axial orientation, 2D, with TE/TR¼ 20/
650 ms, flip angle 20, at 3T, and with
an in-plane resolution of 256x256 voxels
in all cases. The T1-weighted (MPRAGE)
sequence was acquired 3D, with TE/
TR¼ 3.16/6.8 ms, flip angle 8, voxel size
of 111.2 mm3. Although the scanner
vendors and coil models were not the
same in all centres, all sequence parameters
were consistently equal among scanning
waves and across centres.
Image analysis
All (2913) T2*-weighted (GRE) scans,
obtained from each annual visit, were visu-
ally assessed by one observer (Observer 1
[A.H.]) for BMBs within the software pro-
gramme MRIcronVR , version 12.12.2012.
The Brain Observer Microbleed Scale was
used to determine presence, number and
location of BMBs.40 Any black dots initial-
ly rated as uncertain were re-rated defini-
tively after considering symmetry, blood
vessel anatomy and checking for presence
in scans from other visits. Vessel minerali-
zation was also assessed added by the
T1-weighted (MPRAGE) sequence. A
cross-sectional subsample of 150, and a lon-
gitudinal subsample of 20 patients, both
randomly selected, were equally assessed
by a second observer (Observer 2 [LC])
with a similar level of experience and fol-
lowing the same guidelines. All assessments
were done by each observer blind to each
other and to any clinical, demographic or
cognitive data. The time difference between
each observer’s assessments was 1 year.
A third observer (M.C.V.H.) checked each
observer’s results at the time of their respec-
tive assessments, simultaneously viewing all
sequences from the three yearly scans of the
same patient, to guarantee consistency in
the output and decide on ‘uncertain’ cases.
Statistical analyses
All statistical analyses were performed
using the SPSSVR statistical package, version
24.0 (SPSS Inc., Chicago, IL, USA) for
WindowsVR and MATLABVR R2015a
(MathWorksVR Inc., Natick, MA, USA).
In order to analyse the progression of
BMBs, the Mann–Whitney U-test was
used to determine differences in the distri-
bution of BMB prevalence (i.e. the propor-
tion of patients with BMBs) between
cognitive groups each year and the median
number of BMBs in each cognitive group
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Table 1. Clinical data downloaded from the Alzheimer’s Disease Neuroimaging Initiative database and
clinical plausibility and/or previous research for selection.14–39
Clinical data obtained Clinical plausibility and previous research
General information: baseline cognitive status,
age at baseline, sex, years in education,
race, marital status, APOE e4 genotype
Brayne et al., 201014, Charidimou et al., 201315,
Copenhaver et al., 200816, Helmer et al.,
199917, Jeerakathil et al., 200418, Lee et al.,
201119, Poels et al., 201020, Poels et al., 201121,
Romero et al., 201422, Shams et al., 201523,
Sveinbjornsdottir et al., 200824, Tsushima et al.,
200325, Wiegman et al., 201426, Wu et al.,
201427
Baseline cognitive test scores: Clinical
Dementia Rating Scale, Cognitive Subscale
of the AD Assessment Scale (11 and 13),
Mini Mental State Examination, Auditory
Verbal Learning Test, Activities of Daily
Living, Montreal Cognitive Assessment,
Everyday Cognition
References included in Wu et al., 201427 and post
meta-analysis relevant studies: Hilal et al.,
201428, Shams et al., 201523, Yamashiro et al.,
201429
Baseline brain measurements: volumes of
brain ventricles, hippocampus, whole brain
tissue, entorhinal cortex, fusiform gyrus and
middle temporal gyrus, all standardized by
intracranial volume; visual rating scales of
white matter hyperintensities (Fazekas
scale), and perivascular spaces burden
(Potter scale)
Bilello et al., 201530, Chowdhury et al., 201131,
Henneman et al., 200932, Samuraki et al.,
201533, Su et al., 201634
Medical and family history data obtained
at baseline: systolic and diastolic blood
pressure, seated pulse rate, body mass
index, past medical history of cardiovascu-
lar risk factors (cardiovascular disease and
smoking), endocrine-metabolic risk factors,
family history of dementia and family history
of Alzheimer’s Disease
Charidimou et al., 201315, Copenhaver et al.,
200816, Go´mez-Tortosa et al., 201235,
Jeerakathil et al., 200418, Lee et al., 201119,
Poels et al., 201020, Poels et al., 201121,
Romero et al., 201422, Scarabino et al., 201636,
Shams et al., 201523, Sveinbjornsdottir et al.,
200824, Tsushima et al., 200325, Wiegman
et al., 201426, Wu et al., 201427
Baseline subject characteristics: work history
and retirement status
Andel et al., 201537, Leist et al., 201338,
Rijs et al., 201539
Baseline bio-specimen measurements: red
blood cell count (x1012/l), haemoglobin
(g/dl), haematocrit (%), triglycerides
(glycerol phosphate oxidase method)
(mg/dl), serum cholesterol (mg/dl), serum
glucose (mg/dl), creatinine (mg/dl), vitamin
B12 (pg/ml)
Charidimou et al., 201315, Copenhaver et al.,
200816, Jeerakathil et al., 200418, Lee et al.,
201119, Poels et al., 201020, Poels et al., 201121,
Romero et al., 201422, Shams et al., 201523,
Sveinbjornsdottir et al., 200824, Tsushima et al.,
200325, Wiegman et al., 201426, Wu et al.,
201427
Past medical history of cardiovascular risk factors refers to smoking, other risk factors mentioned in the participant’s
medical history, and previous medical reports of having (or not) any cardiovascular disease. The latter referred to/included
the presence of coronary or peripheral artery disease, mild stroke, hypertensive or rheumatic heart disease, cardiomy-
opathy, carditis, heart arrhythmia, or thromboembolic disease. The most common risk factors described in the partic-
ipant’s medical history are hypertension and hypercholesterolaemia.
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each year to evaluate BMB progression (as
defined previously).
In order to analyse the risk factors for
BMB progression, one-way analyses of
covariance (ANCOVA) were performed to
evaluate candidate variables (clinical data)
associated with potential change in BMB
count at each time-point. Since BMB
counts were obtained at three time-points
(year 1 [Y1], year 2 [Y2] and year 3 [Y3]),
the evaluation was performed for potential
change from Y1 to Y2, Y2 to Y3 and Y1 to
Y3. Candidate variables were selected a
priori based on clinical plausibility and/or
previous research (Table 1).14–39 Data
exploration suggested three ANCOVA
analyses for bio-specimens (ANCOVA 1),
brain measurements (ANCOVA 2) and
cognition (ANCOVA 3) should be per-
formed at each time-point. Prior to con-
ducting ANCOVAs, collinearity was
assessed through Belsley collinearity diag-
nostics41 and any covariates found to have
statistically significant associations with
other covariates included in each
ANCOVA were excluded. Independence
between each covariate and the independent
variable and homogeneity of regression
slope assumptions were also tested and
any statistically significant associations
excluded from the analysis. Finally, princi-
pal component analysis was performed
prior to conducting the cognition
ANCOVA to restrict cognitive test scores
to four principal components that explained
78.38% of the variance. Finally, statistically
significant predictors for potential change
in BMB count at each time-point from the
ANCOVAs were then used to calculate
odds ratios to determine whether each pre-
dictor was a factor for BMB progression,
i.e. an increase in BMB count from Y1 to
Y2, Y2 to Y3 or Y1 to Y3. For this, signif-
icant predictors from ANCOVAs were
dichotomized appropriately; presence or
absence for binary factors and clinical cri-
terion used for continuous factors.
Brain microbleed counts reported by
each observer for a subsample of 150
patients (cross-sectional subsample) were
used to assess inter-observer variability on
BMB prevalence per cognitive group.
A Bland-Altman plot was constructed to
evaluate inter-observer differences.42 The
Mann–Whitney U-test was used to deter-
mine whether differences in BMB preva-
lence between cognitive groups were
significant. Cohen’s kappa for BMB pres-
ence/absence and for BMB count were
also calculated, using an online tool
(VR Richard Lowry 2001–2015)43 and the
MATLABVR function kappa, version 1.3
by Giuseppe Cardillo.44
Brain microbleed counts reported by
each observer for a subsample of 20
patients (longitudinal subsample) were
used to assess inter-observer variability on
BMB progression per cognitive group. The
Mann–Whitney U-test was used to deter-
mine significance in the differences in aver-
age (i.e. mean or median depending on
whether the data were normally distributed
or not) BMB prevalence between cognitive
groups. The median number of BMBs
reported by each observer, in each cognitive
group each year, was also calculated.
Differences in BMB counts reported by
each observer were further investigated.
Reported BMB location was considered to
ascertain whether either observer was con-
sistently identifying more BMBs in a partic-
ular location. An experienced observer also
re-assessed scans where inter-observer
differences were reported to investigate fac-
tors that may have confounded BMB
assessments.
Results
In general, BMB progression remained
stable across the three consecutive years in
all cognitive groups despite a BMB count
increase that was observed in some CN
and MCI individuals. As a consequence, it
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was not possible to determine whether
BMB progression in such a short time
frame could be considered an indicator of
cognitive decline, as detailed below.
Sample characteristics
A total of 291 patients were identified
from the ADNI database using the selection
criteria. The descriptive statistics for each
group’s baseline characteristics and
number of BMBs counted by Observer 1
are presented in Table 2. Prevalence of
BMBs in the sample slightly increased
over the three consecutive years (Y1: 66/
291 [22.68%]; Y2: 73/291 [25.09%]; Y3:
80/291 [27.49%]); as did the individual
BMB count per patient (Y1: 55/291
[18.90%]; Y2: 61/291 [20.96%]; Y3: 66/
291 [22.68%]) with 1–2 BMBs and (Y1:
11/291 [3.78%]; Y2: 12/291 [4.12%]; Y3:
14/291 [4.81%]) with  3 BMBs. This
slight increase was observed in CN and
MCI individuals, but not in AD patients.
Of note, 93/291 patients that comprised
this sample were part of the cross-sectional
sample analysed in a previous study.5
BMB progression pattern in the
total sample
Brain microbleed prevalence overall was
higher in the CN group than in the
EMCI, LMCI and AD groups each year,
but these group differences were not signif-
icant. The median number of BMBs per
patient per year (Y1, Y2, Y3) was greater
in the AD group (2.5, 2.5, 2.5) compared
with the CN (1.0, 1.0, 1.0), EMCI (1.0,
1.0, 2.0) and LMCI (1.0, 1.0, 1.0) groups,
but these group differences were not
significant.
In general, from Y1 to Y2, BMB count
increased in 16/291 individuals and
decreased in 8/291 individuals. From Y2
to Y3, BMB count increased in 21/291 indi-
viduals and decreased in 7/291 individuals.
The median increase/decrease counted was
1 BMB. Only 4/291 individuals experienced
a consistent yearly increase in the number
of BMBs.
Factors for BMB progression
Statistically significant predictors for poten-
tial change in BMB count at each time-
point identified by ANCOVA analyses are
shown in Table 3. Total cholesterol was the
main predictor (B¼ 0.002, P< 0.044) when
included in ANCOVA 1. Number of years
in education (B¼ –0.029, P¼ 0.028) and
family history of dementia (B¼ – 0.10,
P¼ 0.028) were also found to be predictors
when included. Family history of AD
(B¼ 0.060, P¼ 0.016) and endocrine-
metabolic risk factors (B¼ 0.10, P¼ 0.044)
were found to predict potential change in
BMB count from Y1 to Y2 in ANCOVAs
2 and 3, respectively. However, as Table 3
shows, significant predictors for potential
change in BMB count at each time-point
could not be considered significant factors
that could potentially increase the likeli-
hood of BMB to occur.
Analyses of inter-observer variation on
BMB progression pattern assessment
Cross-sectional inter-observer differences. Figure
2a shows the Bland-Altman plot. Both
observers had perfect agreement on 68/150
cases. The mean difference of BMB count
between the two observers was 1.47, sug-
gesting a bias toward Observer 2 reporting
a higher count. Inter-observer differences
increased with the increase in the number
of BMBs counted. Observer 2 had a tenden-
cy to report a higher BMB count in the
cortex, a likely explanation for the bias
and increasing difference. Observer 1
found BMBs present in 9/50 CN, 15/54
EMCI, 6/38 LMCI, and 1/8 AD patients
(Figure 2b) and reported a BMB prevalence
lower in CN than EMCI patients. However,
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BMB prevalence was higher in CN than
LMCI and AD patients. None of these dif-
ferences were significant. Observer 2 found
BMBs present in 22/50 CN, 28/54 EMCI,
21/38 LMCI and 4/8 AD patients
(Figure 2b) and reported a BMB prevalence
lower in CN than EMCI, LMCI and AD
patients, but these differences were not sig-
nificant. While the median number of
BMBs found by Observer 1 was slightly
greater in the LMCI group (1.7) than the
CN (1.0), EMCI (1.0) and AD (1.0) groups,
the median number of BMBs found by
Observer 2 was slightly greater in the
EMCI group (3.5) than the AD (2.5), CN
(2.0) and LMCI (2.0) groups.
The overall agreement between
Observers 1 and 2, of having versus not
having BMBs was j¼ 0.543. However,
there was only a slight agreement between
both observers in the exact number of
BMBs counted: unweighted Cohen’s
kappa j¼ 0.058 (95% confidence interval
–0.077, 0.194), with a maximum possible
kappa given the marginal frequencies
j¼ 0.424.
Longitudinal inter-observer differences. Observer
1 found BMBs present in 2/3 CN, 2/12
EMCI and 2/5 LMCI patients (Figure 3)
and reported an average BMB prevalence
higher in CN than EMCI and LMCI
patients, over each year although these dif-
ferences were not significant. Observer 2
found BMBs present in 1/3 CN, 5/12
EMCI and 3/5 LMCI patients (Figure 3)
and reported an average BMB prevalence
higher in LMCI compared with EMCI
and CN patients, over each year.
However, the differences in BMB preva-
lence between cognitive groups were also
not significant. The median number of
BMBs identified by each observer in each
cognitive group per year is detailed in
Table 4. Both observers identified BMB
progression in the CN group each year.
Similarly, for EMCI patients, bothT
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observers found BMB progression from Y1
to Y2 and then regression from Y2 to Y3.
For LMCI patients, both observers identify
BMB progression from Y1 to Y2, but
Observer 2 reported a regression from Y2
to Y3 whereas Observer 1 reported a pro-
gression (Figure 3).
Factors that affected inter-observer reliability and
location of the inter-observer differences.
Observer 2 had a tendency to report a
higher BMB count in the basal ganglia in
the subsample of 20 patients, and in the
cortex in the subsample of 150 patients.
Inter-observer differences were mainly
found in these two locations (i.e. the basal
ganglia and cortex). However, in the sub-
sample of 150 patients, median differences
of 1 BMB were found in the grey/
white matter junction (three cases), brain
stem (six cases), thalami (two cases),
cerebellum (eight cases) and subcortical
white matter (three cases). Vessel calcifica-
tions (Figure 4a), basal ganglia mineralization
(Figure 4b) and reduced cortical thickness
(Figure 4c) hampered identification of ‘true’
BMBs and hence affected inter-observer
reliability.
Discussion
The findings of the current study suggest
that the number of BMBs may increase in
cognitively normal and mild cognitively
impaired individuals but not in patients
with Alzheimer’s disease. However, a pro-
gression pattern was not present, and none
of the factors reported to date to be associ-
ated with BMB prevalence appeared to pre-
dict these results, although total serum
Table 3. One-way analyses of covariance (ANCOVA) results showing statistically significant predictors
for potential change in brain microbleed (BMB) count at each time-point and odds ratios (OR) and 95%
confidence intervals (95% CI) of whether the statistically significant predictors are or are not risk factors for
BMB progression.
ANCOVA 1 – Bio-specimen measurements and other
BMB Y1 to BMB Y2 Cholesterol (B¼ 0.002, SE  0.001, P¼ 0.0097, OR 1.36, 95% CI
0.52, 3.56)
BMB Y2 to BMB Y3 Number of years in education (B¼ –0.029, SE¼ 0.013, P¼ 0.028,
OR 0.60, 95% CI 0.13, 2.64)
BMB Y1 to BMB Y3 Cholesterol (B¼ 0.002, SE  0.001, P¼ 0.044, OR 1.28, 95% CI
0.58, 2.82)
Family history of dementia (B¼ –0.10, SE¼ 0.046, P¼ 0.028, OR
1.01, 95% CI 0.46, 2.23)
ANCOVA 2 – Brain measurements and other
BMB Y1 to BMB Y2 Family history of AD (B¼ 0.060, SE¼ 0.025, P¼ 0.016, OR 1.47,
95% CI 0.52, 4.20)
BMB Y2 to BMB Y3 –
BMB Y1 to BMB Y3 –
ANCOVA 3 – Cognition and other
BMB Y1 to BMB Y2 Endocrine-metabolic risk factors (B¼ 0.10, SE¼ 0.050, P¼ 0.044,
OR 1.33, 95% CI 0.51, 3.46)
BMB Y2 to BMB Y3 –
BMB Y1 to BMB Y3 –
BMB Y1, BMB count in year [Y] 1 (first visit) brain scan; BMB Y2, BMB count in Y2 (second visit) brain scan;
B, un-standardized regression coefficient; SE, standard error; BMB Y3, BMB count in Y3 (third visit) brain scan;
AD, Alzheimer’s Disease.
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Figure 2. Baseline inter-observer variability and brain microbleed (BMB) prevalence. (a) Bland-Altman plot
for BMB count. The difference in BMB count between observers is plotted against the mean BMB count for
150 patients. It increased with the increase of the mean number of BMB counted by both observers. The
mean difference of BMB count between observers is 1.47 (95% confidence interval [–3.7, 6.2], suggesting a
bias towards Observer 2 reporting a higher count. Larger circles in the graph represent greater numbers of
observer comparisons for these data points. (b) Percentage of patients with BMBs in each cognitive group
reported by each observer in the same subsample of 150 patients. CN, cognitively normal; EMCI, early mild
cognitive impairment; LMCI, late mild cognitive impairment; AD, Alzheimer’s Disease. The colour version of
this figure is available at: http://imr.sagepub.com.
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cholesterol was identified as the main
potential predictor of the change in BMB
count at each time-point. Despite equal
assessment conditions, inter-observer varia-
tions can be considered problematic in the
assessment of BMB progression; their vari-
ation seems to have little influence in the
analysis of BMB progression in the
sample, not so in individual cases.
Contrary to our hypothesis, progression
of BMBs in CN and MCI groups of individ-
uals could not be ascertained, as it was
observed only in a small proportion of indi-
viduals from each group. BMB prevalence
remained stable in all AD patients as hypoth-
esized. However, the AD group of patients
had higher median number of BMBs than
the other three groups. The lack of progres-
sion maybe due to the low prevalence of vas-
cular risk factors in AD patients compared
with the other groups of individuals. Despite
considerable heterogeneity within the exist-
ing literature, these current findings contrast
with the general trend reported.1 For
example, the Rotterdam study investigated
elderly individuals without dementia and
reported progression in BMB prevalence
from 24.4% at baseline to 28.0% after
three years.21 Although a percentage of CN
individuals with BMBs in this current study
showed similar progression, increasing from
25.51% to 28.57% three years later, in our
case this increase was not significant in the
overall sample. Possible explanations for this
discrepancy include differences in sample
sizes, study population characteristics, MRI
sequences and imaging parameter choices,
inter-observer variation and/or observer
experience. Many studies described in a
review1 used small sample sizes,10,45–47 par-
ticularly for CN controls, which may not be
representative of BMB prevalence per
Figure 3. Longitudinal inter-observer differences per cognitive group in 20 patients. Each patient is rep-
resented by a different colour and the patient colours correspond for both observers. *Representative of
more than one patient. Brain microbleed (BMB) count refers to the number of BMBs that each observer
counted on each scan. CN, cognitively normal; EMCI, early mild cognitive impairment; LMCI, late mild
cognitive impairment. The colour version of this figure is available at: http://imr.sagepub.com.
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cognitive group. MRI sequence and imaging
parameter choice can also affect BMB iden-
tification with susceptibility-weighted images
enhancing the susceptibility-related con-
trasts, and higher magnetic fields increasing
the contrast-to-noise ratio and the BMB
size.48 Different study sample characteristics
may also have influenced BMB prevalence.
The current sample was not representative of
the general population, as individuals that
have baseline MRI scans with evidence of
infarction or other focal lesions, presence
of multiple lacunes or lacunes in a critical
memory structure, and/or other brain
structural abnormalities are excluded from
ADNI, hence only individuals with absence
or mild presence of vascular pathology are
included. Moreover, in the current sample,
the mean age in the CN group (74 years)
was slightly higher than the EMCI and
LMCI groups (70 and 71 years, respectively);
and the proportion of CN individuals with
two cardiovascular risk factors (29.59%) was
also greater than for the EMCI and LMCI
groups (26.00% and 21.05%, respectively)
and AD (5.88%) patients. BMB prevalence
is known to increase with age and cardiovas-
cular risks.20,22,23 Finally, accurate BMB
Figure 4. Factors that affected inter-observer variability as seen on magnetic resonance imaging
T2*-weighted gradient-recalled echo images (arrows): (a) vessel calcifications; (b) basal ganglia mineraliza-
tion; (c) reduced cortical thickness.
Table 4. Median number of brain microbleeds (BMBs) identified by each observer in each cognitive group
each year on a subsample of 20 patients.
Observer 1 Median number of BMBs Observer 2 Median number of BMBs
Year 1 Year 2 Year 3 Year 1 Year 2 Year 3
CN 1.0 1.0 1.0 3.0 5.0 6.0
EMCI 2.5 2.5 2.5 5.0 6.0 5.0
LMCI 1.5 1.5 1.5 2.0 3.0 2.0
CN, cognitively normal; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment.
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identification is crucial to reporting BMB
prevalence, and to our knowledge, this has
not been analysed in any of the previous lon-
gitudinal studies of BMB progression.
No specific clinical risk factors predicted
BMB progression. The association of
specific clinical risk factors with BMBs is
somewhat conflicting in the existing litera-
ture. For example, a study found low total
cholesterol to be associated with BMB
prevalence,22 whereas this study found ele-
vated total cholesterol to predict potential
change in BMB count from Y1 to Y2 and
Y1 to Y3. This latter finding is more con-
sistent with that reported in a study of
dementia patients, with BMB prevalence
increasing with hyperlipidaemia and with
MCI patients with hyperlipidaemia having
increased BMB counts.23 Similarly, conflict-
ing findings have been reported for
endocrine-metabolic risk factors, specifically
diabetes.21,23 There is a dearth of information
on factors and neuropathological markers of
cognitive decline and dementia progression,
which include years in education, family his-
tory of AD and BMBs.14,35,36 The present
study is specific to factors that contribute to
potential change in BMB count and therefore
not directly comparable with research on
cognitive decline per se.
Odds ratios were small with confidence
intervals overlapping one in the current
study. Predictors derived from ANCOVA
models may not have translated into signif-
icant odds ratios due to sample size and/or
small effect size of putative risk factors,
and/or dichotomization. Change of the
number of BMBs counted in the period
analysed was only observed in less than 30
patients. Such sample sizes may have been
too small to produce significant findings.
Furthermore, the predictors determined by
ANCOVA had to be dichotomized to cal-
culate odds ratios. Such dichotomization
may have resulted in loss of statistical
power. Indeed, two studies investigating
risk factors associated with BMBs used
much larger samples sizes and logistic
regression models to avoid limitations asso-
ciated with dichotomization.20,22 They still
reported odds ratios and confidence inter-
vals quite close to (and often overlapping)
one. The progression of other markers of
cerebral small vessel disease like white
matter hyperintensities could predict the
progression of BMBs. However, only visual
ratings of white matter hyperintensities and
perivascular spaces at Y1 were available for
the analyses. Future longitudinal studies
require larger sample sizes, quantitative
measures of small vessel disease indicators
at each time-point and/or alternative statis-
tical approaches to fully investigate risk fac-
tors for BMB progression.
Variation in inter-observer differences
was observed in the current study. Bland-
Altman analysis found a bias towards
Observer 2 reporting a higher BMB count,
with an increased difference as BMB count
increased. However, the analysis of the
overall BMB progression in the sample
yielded similar results for both observers.
Despite recognition of large ranges of
inter-observer reliability within the existing
literature,40 there are no guidelines on what
constitutes clinically acceptable bias/limits
of agreement. Most studies have reported
kappa statistics; however, this parameter is
limited in interpreting the extent of agree-
ment, with the quantitative value being
qualitatively described as slight, fair, mod-
erate etc. For consistency in the way results
are reported and to allow comparability
with other studies, this current study also
reported kappa statistics. Bland-Altman
methodology, though, is more appropriate
to parametric data, permitting the meaning-
fulness of change to be determined within
the context of the measurement scale (i.e.
the 95% limits of agreement are placed in
‘test score’ units in contrast to kappa).
Factors found to affect inter-observer
reliability have previously been reported as
those confounding BMB detection.11,49,50
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Basal ganglia mineralization is likely to
explain Observer 2’s tendency to report a
higher BMB count in the basal ganglia,
and vessel calcifications and reduced corti-
cal thickness, hampering differentiation
between BMBs and vessel calcification,
explaining the higher BMB count reported
for the cortex. A previous study on 100 CN
community-dwelling individuals aged 73
years showed a positive and strong correla-
tion and considerable overlap between cal-
cified regions and other regions with iron
accumulation in its different forms.52,51
Others have suggested a shared pathway
for the age-related deposition of both min-
erals in the brain, occasionally attributed to
the primary accumulation of one followed
by the other;53 or to a shared transport
mechanism that manifests in the deposition
of both minerals in the vicinities of the
blood vessels.54 These may partly explain
why inter-observer differences increased
with the increase of the BMB count and
the consistency in the overall progression
pattern of BMBs found by both observers
despite the influence that the inter-observer
differences had on the assessment of the
BMB progression in individual cases.
Future studies should seek to reduce inter-
observer variation and there should be a
clinical consensus on acceptable bias/limits
of agreement.
This study had a number of strengths
and limitations. To the best of our knowl-
edge, this is the first study that assesses the
reproducibility of longitudinal measure-
ments of BMBs, as such contributing to
the emerging field of research on BMBs as
potential pathological markers within the
spectrum of cognitive decline. Strengths
of this study also include the large number
of individuals assessed under the same
MRI protocol using well-validated BMB
guidelines and the wide variety of relevant
participant data available. The observers
were blinded to clinical data, including cog-
nitive status, throughout image analysis.
A limitation of this study was the relatively
small AD group. Longitudinal study designs
and the nature of AD may impede obtaining
comparatively sized AD groups;55 however,
future studies should try to secure larger AD
populations to facilitate valid comparisons.
This study was also limited by the inclusion/
exclusion criteria of the ADNI database,
a cohort not entirely representative of the
general population.56 Individuals with sub-
stantial small vessel disease are excluded
from ADNI and therefore AD patients
are likely to be more genetically prone to
the disease. Clinical study data included
were also restricted to available ADNI data-
base parameters collected across multiple
sites. Although a general protocol is in
place, variations in techniques and data col-
lection methodologies are likely. The loca-
tion of BMBs was not statistically analysed
in this study. Lobar BMBs have been previ-
ously found to be associated with longitudi-
nal cognitive decline, whereas BMBs located
in the deep grey matter and infratentorial
brain revealed no significant associations.57
BMBs in all regions were included in this
study, potentially diluting findings. A further
limitation is the failure to apply a Bonferroni
correction to the ANCOVA models that
would have resulted in a more stringent cri-
terion for statistical significance. Finally,
intra-observer variation was not considered
here due to time constraints; such measure-
ments are also important to determine,
although might reasonably be expected to
be less than inter-observer variations.
Brain microbleed prevalence and count
appeared to progress in CN and MCI indi-
viduals but not in AD patients; however,
differences between cognitive groups were
not significant and the median number of
BMBs tended to remain stable in each
group over time. No significant progression
pattern was found in the sample analysed,
although as noted above this sample may
not be representative of the general ageing
population. Although total cholesterol,
Harper et al. 17
years in education, family history of demen-
tia and AD, and endocrine-metabolic risk
factors were weakly predictive of potential
change in BMB count at certain time-
points, they were not significant risk factors
for BMB progression. Finally, despite equal
conditions, inter-observer differences were
found and inter-observer variation is likely
to have influenced BMB progression pat-
tern assessment. Therefore, this report
cannot exclude BMB progression in AD
patients.
While this study highlights the impor-
tance of reporting inter-observer variation,
future studies should seek to reduce inter-
observer differences. Similar inter-observer
variation analyses could be performed
for computational rather than visual assess-
ments of BMBs, to determine whether com-
putational assessment methods are more
reliable. Repeating this study in a few
years may yield different results as the cog-
nitive status of individuals enrolled in
ADNI is likely to advance along the contin-
uum of cognitive decline and more patients
are likely to have had three consecutive
study visits, minimizing AD group limita-
tions. A similar study could also be per-
formed in a larger sample of patients,
adjusting for baseline characteristics, and
across a wider spectrum of cognitive decline.
Also, analysing a wider interval between
assessments and/or increasing the number
of yearly assessments (i.e. analysing progres-
sion in 4 or more years) would be clinically
important. Analysis of BMB location may
also be informative. Such a study is likely
to provide useful information on BMB pro-
gression and associated risk factors, confirm-
ing or otherwise the potentially valuable role
of BMBs as a differential indicator of cogni-
tive decline.
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